Drug profile

The FDA adverse-event record for Unspecified Subcutaneous Fluids

41 adverse-event reports submitted to the FDA Center for Veterinary Medicine reference Unspecified Subcutaneous Fluids. See the species affected, top reactions, and outcomes below.

41
adverse-event reports
26.8%
death-coded share
Dog
most-reported species
11
Diarrhoea - top reaction
Verify with FDA CVM →
Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
41
Total Reports
11
Deaths Reported
26.8%
Death Rate

Active Ingredients

Unspecified Subcutaneous Fluids

Administration Routes

SubcutaneousUnknown

Species Affected

Dog 24
Cat 17

Most Affected Breeds

Domestic Shorthair 14
Retriever - Labrador 4
Chihuahua 3
Greyhound - Italian 2
Crossbred Canine/dog 2
Terrier - Rat 1
Russian 1
Boxer (German Boxer) 1
Griffon - Brussels 1
Poodle - Miniature 1

Most Reported Reactions

Diarrhoea 11
Not eating 9
Vomiting 9
Lethargy (see also Central nervous system depression in Neurological) 9
Anorexia 7
Death by euthanasia 7
Musculoskeletal disorder NOS 6
Lethargy (see also Central nervous system depression in 'Neurological') 5
Weight loss 5
Behavioural disorder NOS 4
Not drinking 4
Weakness 4

Outcome Breakdown

Ongoing
16 (39.0%)
Outcome Unknown
7 (17.1%)
Recovered/Normal
7 (17.1%)
Euthanized
7 (17.1%)
Died
4 (9.8%)

Unspecified Subcutaneous Fluids Adverse Event Insights

41 reports name Unspecified Subcutaneous Fluids; 11 recorded a death outcome (26.8% of reported events, not a population-level mortality rate). Active ingredient: Unspecified Subcutaneous Fluids. Administration routes: Subcutaneous, Unknown.

By species: Dog (24 reports), Cat (17 reports). By breed: Domestic Shorthair (14), Retriever - Labrador (4), Chihuahua (3).

Leading clinical signs: Diarrhoea (11), Not eating (9), Vomiting (9), Lethargy (see also Central nervous system depression in Neurological) (9). Outcome, 41 coded reports: Ongoing leads at 39.0%.

Read these counts as reporting volume, not risk: per our methodology, a widely-prescribed drug will rack up more raw FDA reports in a given year than a rarely-used one at an identical true rate, so we recommend comparing within similar-exposure products rather than across the full 2025 catalog.

Source: FDA Center for Veterinary Medicine openFDA Animal & Veterinary Adverse Events (CVM AER) · 2025

Every figure on PlainBreed is rendered directly from FDA openFDA adverse event data, no number is typed in by an editor. This page draws directly on FDA openFDA data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.